Tuesday, 02 January 2024 12:17 GMT

Paul Leonard


(MENAFN- The Conversation)
  • Associate Professor in Biotherapeutics, Dublin City University
Profile Articles

Associate Professor in Biotherapeutics at Dublin City University (DCU) leading research in biomolecular interaction analysis, technology development (including software and hardware), single cell analysis, biologics discovery and diagnostics across multiple application areas including oncology, cardiovascular and infectious disease (Sept 2023 - present).

Innovative entrepreneur and technology inventor with 20 year's post Ph.D. experience in academic and industrial research and senior management roles in clinical and pre-clinical stage companies. Co-founder and previous CSO/CTO of Remedy Biologics Ltd. Spun the company out of Dublin City University, raising >€15M in non-dilutive and equity-based financing (Feb 2017 to July 2023).

Research interests include:

(i) Single-cell analysis for biological discovery

(ii) Technologies for improved antibody and cell therapy discovery

(iii) High throughput biomolecular interaction technologies and studies

(iv) Immunoassay development and validation for biomedical and environmental analysis

Experience
  • –present Associate Professor in Biotherapeutics, Dublin City University

The Conversation

MENAFN10092026000199003603ID1111649175



The Conversation

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story